See the DrugPatentWatch profile for Breztri
What will Breztri cost versus Trelegy in 2026?
Breztri (budesonide/glycopyrrolate/formoterol) and Trelegy (fluticasone/umeclidinium/vilanterol) are both once-daily inhaler options used for COPD (and Trelegy also for asthma). A 2026 “cost comparison” depends mainly on insurance coverage, pharmacy pricing tier, and whether you’re buying under Medicare Part D, using manufacturer copay cards, or paying cash.
With the information provided here, I can’t give a reliable 2026 price-per-inhaler estimate for your exact location or coverage situation.
What prices should you compare (to avoid misleading “headline” numbers)?
If you’re comparing 2026 costs, compare the same out-of-pocket measure for each inhaler:
- Cash price at your preferred pharmacy (or a consistent online price).
- Your expected copay under your plan.
- Your estimated “net” cost after pharmacy discounts and any manufacturer assistance (if you qualify).
- Whether the inhaler is covered as preferred (lower copay) or non-preferred (higher copay).
Even two people in the same year can pay very different amounts because COPD inhalers can land on different formulary tiers.
How to check your 2026 out-of-pocket cost quickly
To get a real-world Breztri vs Trelegy comparison for 2026, check:
1. Your plan’s formulary entry (Breztri and Trelegy) and formulary tier.
2. Prior authorization or step-therapy rules (these can affect whether you pay full price).
3. Whether your plan offers an inhaler “brand copay cap” or negotiated pricing.
4. Your deductible status (common in early 2026).
Are Breztri and Trelegy likely to change in price in 2026 due to patents?
Prices can shift when exclusivity ends or biosimilar/generic competition changes the market. For inhaler brands, the most relevant question is whether generic or authorized alternatives are available and how payers respond.
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and can help you understand whether timing could affect future pricing. You can use it to check the legal/patent landscape for Breztri and Trelegy.
DrugPatentWatch.com:
- https://www.drugpatentwatch.com/
What you can do if one is much more expensive than the other
If your 2026 plan makes one inhaler costly:
- Ask your prescriber whether switching to the alternative inhaler fits your condition and prior response.
- Ask the pharmacy about therapeutically equivalent alternatives on your formulary.
- Ask whether manufacturer assistance or a copay card applies (eligibility rules vary).
- If you have Medicare, confirm whether your plan is Part D (and whether you hit the coverage gap/“donut hole” affecting your cost).
If you tell me your situation, I can narrow the comparison
If you share:
- your country (US or other),
- whether you have Medicare Part D, Medicaid, employer insurance, or pay cash,
- your pharmacy (e.g., CVS/Walgreens/etc.),
- the exact strengths you’re prescribed (or just “Breztri Aerosphere” and “Trelegy Ellipta”),
I can help you translate your plan coverage into a realistic 2026 cost comparison.
Sources cited
- [1] https://www.drugpatentwatch.com/